Literature DB >> 20512538

Glucose transporter-1 (GLUT-1) immunoreactivity in benign, premalignant and malignant lesions of the gallbladder.

Mateja Legan1, Spela Tevžič, Ana Tolar, Boštjan Luzar, Vera Ferlan Marolt.   

Abstract

GLUT-1 is a transmembrane glucose transport protein that allows the facilitated transport of glucose into cells, normally expressed in tissues which depend mainly on glucose metabolism. Enhanced expression of GLUT-1 can also be found in a large spectrum of carcinomas. This study aimed to investigate GLUT-1 expression in gallbladder tissue: from normal tissue samples, hyperplasias, low-grade and high-grade dysplasias to gallbladder carcinomas. In all, 115 archived samples of gallbladder tissue from 68 patients, presented after cholecystectomy, were immunohistochemically stained for GLUT-1. According to the intensity of GLUT-1 immunoreactivity, samples were divided into negative (stained 0-10% of cells stained), positive with weak to moderate (10-50%) and positive with strong (>50%) GLUT-1 expression. The GLUT-1 immunoreactivity of the samples showed a characteristic increase from premalignant lesions to carcinomas. Normal gallbladder tissue samples did not express GLUT-1 (100%). Weak expression was shown only focally in hyperplasias, but to a greater extent with low-grade dysplasias (20%), high-grade dysplasias (40%) and carcinomas (51.8%). Normal gallbladder tissue is GLUT-1 negative. GLUT-1 expression in carcinoma tissue is significantly higher than in dysplastic lesions. Strong GLUT-1 expression indicates 100% specificity for detecting gallbladder carcinomas. Therefore, GLUT-1 is a candidate as a diagnostic as well as a tissue prognostic marker in gallbladder carcinoma patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20512538     DOI: 10.1007/s12253-010-9281-7

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  27 in total

1.  Preneoplastic lesions and gallbladder cancer: an estimate of the period required for progression.

Authors:  I Roa; J C Araya; M Villaseca; X De Aretxabala; P Riedemann; K Endoh; J Roa
Journal:  Gastroenterology       Date:  1996-07       Impact factor: 22.682

2.  The utility of GLUT-1 immunolocalization in cell blocks: An adjunct to the fine needle aspiration diagnosis of cystic squamous lesions of the head and neck.

Authors:  Vishal S Chandan; William C Faquin; David C Wilbur; Kamal K Khurana
Journal:  Cancer       Date:  2006-04-25       Impact factor: 6.860

3.  The blood-nerve barrier is rich in glucose transporter.

Authors:  S C Froehner; A Davies; S A Baldwin; G E Lienhard
Journal:  J Neurocytol       Date:  1988-04

Review 4.  The glucose transporter family: structure, function and tissue-specific expression.

Authors:  G W Gould; G D Holman
Journal:  Biochem J       Date:  1993-10-15       Impact factor: 3.857

5.  GLUT-1 is preferentially expressed in atypical endometrial hyperplasia and endometrial adenocarcinoma.

Authors:  Amanda Ashton-Sager; Augusto F G Paulino; Alaa M Afify
Journal:  Appl Immunohistochem Mol Morphol       Date:  2006-06

6.  Expression of facilitative glucose transporters in gastric tumors.

Authors:  Y Noguchi; D Marat; A Saito; T Yoshikawa; C Doi; K Fukuzawa; A Tsuburaya; S Satoh; T Ito
Journal:  Hepatogastroenterology       Date:  1999 Jul-Aug

7.  Expression of cyclooxygenase-2, glucose transporter-1 and angiogenesis in gallbladder carcinomas and their impact on prognosis.

Authors:  Mateja Legan; Bostjan Luzar; Vera Ferlan Marolt
Journal:  Scand J Gastroenterol       Date:  2009       Impact factor: 2.423

8.  Glucose transporter-1 gene expression is associated with pancreatic cancer invasiveness and MMP-2 activity.

Authors:  Hiromichi Ito; Mark Duxbury; Michael J Zinner; Stanley W Ashley; Edward E Whang
Journal:  Surgery       Date:  2004-09       Impact factor: 3.982

9.  GLUT1 glucose transporter expression in colorectal carcinoma: a marker for poor prognosis.

Authors:  R S Haber; A Rathan; K R Weiser; A Pritsker; S H Itzkowitz; C Bodian; G Slater; A Weiss; D E Burstein
Journal:  Cancer       Date:  1998-07-01       Impact factor: 6.860

Review 10.  Nutritional and physiological consequences of tumour glycolysis.

Authors:  W L Dills
Journal:  Parasitology       Date:  1993       Impact factor: 3.234

View more
  4 in total

Review 1.  Cyclooxygenase-2, p53 and glucose transporter-1 as predictors of malignancy in the development of gallbladder carcinomas.

Authors:  Mateja Legan
Journal:  Bosn J Basic Med Sci       Date:  2010-08       Impact factor: 3.363

2.  Preoperative fasting hyperglycemia is an independent prognostic factor for postoperative survival after gallbladder carcinoma radical surgery.

Authors:  Peng Zheng; Xiaoqian Wang; Zhong Hong; Feixia Shen; Qiyu Zhang
Journal:  Cancer Manag Res       Date:  2019-02-12       Impact factor: 3.989

3.  Role and mechanism of Glut-1 and H+/K+-ATPase expression in pepsin-induced development of vocal cord leukoplakia.

Authors:  Yin-Jie Ao; Ting-Ting Wu; Zai-Zai Cao; Shui-Hong Zhou; Yang-Yang Bao; Li-Fang Shen
Journal:  Eur Arch Otorhinolaryngol       Date:  2021-11-20       Impact factor: 2.503

4.  Glucose transporters as markers of diagnosis and prognosis in cancer diseases.

Authors:  Leszek Szablewski
Journal:  Oncol Rev       Date:  2022-02-22
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.